The short answer
Foundayo is the brand name for orforglipron, an oral small-molecule GLP-1 receptor agonist FDA approved on April 1, 2026. It is indicated, with a reduced-calorie diet and increased physical activity, for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related comorbidity. It is not approved to treat diabetes or menopause symptoms.
Boxed warning: risk of thyroid C-cell tumors
The Foundayo label carries a boxed warning about thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with Multiple Endocrine Neoplasia syndrome type 2.
Other labeled risks include pancreatitis, gallbladder disease, acute kidney injury associated with volume depletion, severe gastrointestinal adverse reactions, hypoglycemia with certain diabetes medicines, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, and suicidal behavior or thinking. The complete label—not a summary page—governs use.
Established evidence
What Foundayo is approved to treat
The FDA-approved use is chronic weight management in adults with obesity, or adults with overweight and at least one weight-related comorbidity, together with a reduced-calorie diet and increased physical activity. Concomitant use with another GLP-1 receptor agonist is not recommended.
Established evidence
How an oral small-molecule GLP-1 works
Orforglipron activates the GLP-1 receptor. Unlike peptide GLP-1 medicines, it is a small molecule taken by mouth. GLP-1 receptor signaling can reduce calorie intake through appetite pathways and affects glucose-dependent insulin and glucagon responses. Route and chemistry do not make it risk-free.
Established evidence
What the phase 3 evidence showed
The ATTAIN-1 randomized trial evaluated adults with obesity or overweight without diabetes and found greater mean weight reduction with orforglipron than placebo over 72 weeks. Individual outcomes varied, gastrointestinal adverse events were common, and trial results should not be converted into a personal forecast.
Established evidence
Foundayo weight-loss results: what averages mean
Trial publications report average changes across randomized groups, not guaranteed outcomes for an individual. Results depend on the studied population, assigned dose, treatment duration, adherence, lifestyle intervention, discontinuations, and how missing data were handled.
Comparing a Foundayo percentage with a number from a separate semaglutide or tirzepatide trial is not a head-to-head comparison. Different enrollment criteria and methods can make cross-trial rankings misleading.
Not established
What is not an approved indication
- Foundayo is not FDA approved to treat menopause symptoms.
- The initial label does not approve it as a treatment for type 2 diabetes.
- Approval does not establish that it is appropriate for every person seeking weight loss.
- This page does not establish Kindr Health availability, coverage, or price.
Established evidence
Foundayo side effects and serious labeled risks
Gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia are common with GLP-1 receptor agonism. The label also addresses pancreatitis, gallbladder disease, acute kidney injury associated with volume depletion, severe gastrointestinal reactions, hypersensitivity, hypoglycemia with certain diabetes medicines, diabetic-retinopathy complications in people with type 2 diabetes, and suicidal behavior or thinking.
Persistent vomiting or diarrhea can lead to dehydration and kidney injury. Severe or concerning symptoms need prompt clinical assessment. Pregnancy, other medicines, planned procedures, and a history of pancreatic, gallbladder, kidney, retinal, or severe gastrointestinal disease can materially affect decisions.
Established evidence
An oral GLP-1 is not the same as a supplement
Foundayo is a prescription medicine with a boxed warning, contraindications, drug-interaction considerations, and required clinical screening. “Oral” describes how it is taken; it does not mean over-the-counter, compounded, or suitable for self-directed use. The current prescribing information controls administration instructions.
How Foundayo differs from injectable GLP-1 medicines
Foundayo is taken orally and is a small molecule. Semaglutide and tirzepatide products differ in molecular structure, receptor activity, dosing, approved indications, evidence, and warnings. Cross-trial percentages do not prove one medicine is better for a particular person.
Foundayo cost, coverage, and availability
Price and coverage searches can change rapidly after a new approval. Out-of-pocket cost depends on the prescribed product, insurance, deductible, pharmacy, location, and any current manufacturer-program terms. This page does not publish an unverified list price, promise coverage, or state that Kindr Health offers Foundayo.
Questions, answered
What people ask about Foundayo
Is Foundayo FDA approved?+
Yes. FDA approved Foundayo (orforglipron) on April 1, 2026 for the chronic weight-management indication described in its label.
Is Foundayo an oral GLP-1?+
Yes. Orforglipron is an oral, small-molecule GLP-1 receptor agonist.
Is Foundayo approved for diabetes?+
No. The initial U.S. approval is for chronic weight management in a defined adult population, not type 2 diabetes treatment.
Does Foundayo have a boxed warning?+
Yes. The label carries a boxed warning concerning the risk of thyroid C-cell tumors and lists related contraindications.
Is Foundayo a pill or an injection?+
Foundayo is an oral small-molecule GLP-1 receptor agonist. It is a prescription medicine, not a supplement.
How much does Foundayo cost?+
A dependable personal cost requires a current benefit and pharmacy check. Insurance, deductible, pharmacy, location, and manufacturer-program rules can all change the amount paid.
Is Foundayo the same as oral semaglutide?+
No. Orforglipron and semaglutide are different molecules with different product labels, evidence, and administration requirements.
Can I get Foundayo through Kindr Health?+
This educational page does not claim that Foundayo is available through Kindr Health.
Kindr Health does not claim to offer Foundayo on this page. Availability and prescribing are not implied.
A broader care pathway
Explore metabolic care
Review Kindr Health care pathways without assuming that Foundayo is offered or appropriate.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- FOUNDAYO (orforglipron) prescribing information (2026) — U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
- FDA approves first new molecular entity under National Priority Voucher Program (2026) — U.S. Food and Drug Administration. www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- Orforglipron for obesity without diabetes (2025) — The New England Journal of Medicine. pubmed.ncbi.nlm.nih.gov/40960239
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.